Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

NCT07667400 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT07667400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07667400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 19, 2026
Completion date
October 1, 2037
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma, carcinoma of larynx, head and neck cancer, head and neck squamous cell carcinoma, hypopharyngeal cancer, metastatic castration resistant prostate cancer, nasopharyngeal carcinoma, oral squamous cell carcinoma, oropharyngeal squamous cell carcinoma, paranasal sinus neoplasms, prostate cancer, salivary gland cancer